Kalaris Therapeutics, Inc. Common Stock (KLRS) Stock
Key stats
- Market cap
- $56.18M
- Price / Earnings ratio
- -1.1x
- EPS (TTM)
- -$2.02
- Volume
- Loading
- 52-week high
- $11.88
- 52-week low
- $1.78
Source: third-party data provider, as of November 7, 2026
Compare with KLRS
Recent news
No recent news
Technical indicators
- RSI 14
- 52.35
- MACD 12/26/9
- -0.19
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.08
- SMA 50
- $2.79
- Price below SMA 50
- EMA 50
- $2.69
- Price below EMA 50
- SMA 200
- $5.26
- Price below SMA 200
- EMA 200
- $4.97
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About Kalaris Therapeutics, Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew Oxtoby | President, CEO & Director | 1974 |
| Ms. Liisa Ann Bayko M.B.A. | CFO & Treasurer | 1971 |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder | 1968 |
| Dr. Michael Philip Dybbs Ph.D. | Co-Founder & Director | 1975 |
| Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder | 1957 |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer | 1971 |
| Ms. Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller | 1989 |
| Ms. Kristine Curtiss | Senior Vice President of Clinical | — |
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 52.35
- MACD 12/26/9
- -0.19
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.08
- SMA 50
- $2.79
- Price below SMA 50
- EMA 50
- $2.69
- Price below EMA 50
- SMA 200
- $5.26
- Price below SMA 200
- EMA 200
- $4.97
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -22.9 | -0.2 | -26.3 | -28.8 | +18.0 |



